Can vaginal lactobacillus suppositories help reduce urinary tract infections?

Lactobacillus Recurrent urinary tract infections Vaginal health Vaginal probiotic Vaginal supplement

Journal

International urogynecology journal
ISSN: 1433-3023
Titre abrégé: Int Urogynecol J
Pays: England
ID NLM: 101567041

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 02 02 2023
accepted: 21 04 2023
medline: 28 11 2023
pubmed: 1 7 2023
entrez: 1 7 2023
Statut: ppublish

Résumé

Recurrent urinary tract infections (rUTIs) are a burden to patients and the health care economy. Vaginal probiotics and supplements have gained significant attention in mainstream media and lay press as a non-antibiotic alternative. We performed a systematic review to determine whether vaginal probiotics are an effective means of prophylaxis for rUTI. A PubMed/MEDLINE article search was performed from inception to August 2022 for prospective, in vivo use of vaginal suppositories for the prevention of rUTIs. Search terms included: vaginal probiotic suppository (34 results), vaginal probiotic randomized (184 results), vaginal probiotic prevention (441 results), vaginal probiotic UTI (21 results), and vaginal probiotic urinary tract infection (91 results). A total of 771 article titles and abstracts were screened. A total of 8 articles fit the inclusion criteria and were reviewed and summarized. Four were randomized controlled trials, with 3 of the studies having a placebo arm. Three were prospective cohort studies, and 1 was a single arm, open label trial. Five of the 7 articles that specifically evaluated for rUTI reduction with vaginal suppositories did find a decreased incidence with probiotic use; however, only 2 had statistically significant results. Both of these were studies of Lactobacillus crispatus and were not randomized. Three studies demonstrated the efficacy and safety of Lactobacillus as a vaginal suppository. Current data support the use of vaginal suppositories containing Lactobacillus as a safe, non-antibiotic measure, but actual reduction of rUTI in susceptible women remains inconclusive. The appropriate dosing and duration of therapy remain unknown.

Identifiants

pubmed: 37392226
doi: 10.1007/s00192-023-05568-4
pii: 10.1007/s00192-023-05568-4
pmc: PMC10682044
doi:

Substances chimiques

Suppositories 0

Types de publication

Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2713-2718

Informations de copyright

© 2023. The Author(s).

Références

Int J Antimicrob Agents. 2006 Aug;28 Suppl 1:S30-4
pubmed: 16859900
Int J Urol. 2021 Oct;28(10):1026-1031
pubmed: 34258813
Urology. 2019 Jun;128:47-54
pubmed: 30796990
Clin Ther. 1992 Jan-Feb;14(1):11-6
pubmed: 1576619
J Urol. 2021 Sep;206(3):688-695
pubmed: 34233479
Infect Dis Clin North Am. 2014 Mar;28(1):1-13
pubmed: 24484571
Scand J Prim Health Care. 1994 Dec;12(4):239-43
pubmed: 7863140
Clin Infect Dis. 2011 May;52(10):1212-7
pubmed: 21498386
BJOG. 2020 Jan;127(2):287-299
pubmed: 31299136
Pharmacol Res Perspect. 2021 Oct;9(5):e00787
pubmed: 34609059
J Obstet Gynaecol. 2018 Jul;38(5):693-696
pubmed: 29526145
Res Microbiol. 2017 Nov - Dec;168(9-10):782-792
pubmed: 28435139
Dis Mon. 2003 Feb;49(2):53-70
pubmed: 12601337
Infect Dis Obstet Gynecol. 2007;2007:35387
pubmed: 18288237
PLoS One. 2014 Aug 22;9(8):e105998
pubmed: 25148517
FEMS Immunol Med Microbiol. 1993 Apr;6(4):251-64
pubmed: 8499891
Sci Rep. 2022 Feb 17;12(1):2698
pubmed: 35177690
Arch Gynecol Obstet. 2014 Mar;289(3):479-89
pubmed: 24170161
Can J Microbiol. 1988 Mar;34(3):339-43
pubmed: 3138016
Anaerobe. 2011 Dec;17(6):410-3
pubmed: 21549209
Br J Gen Pract. 2022 Mar 31;72(717):e252-e260
pubmed: 35314431

Auteurs

Poone S Shoureshi (PS)

Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. poone.shoureshi@cshs.org.

Clarissa Niino (C)

Department of Obstetrics & Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Karyn S Eilber (KS)

Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH